Teva Inks $4.35bn Nationwide US Opioids Settlement Agreement
US-Wide Documentation To Be Finalized ‘Within The Coming Weeks’
Teva is to put more than $3bn in cash on the table over the next 13 years to resolve longstanding opioid-related claims against the company in the US.
You may also be interested in...
Teva will pay $931,
Teva has made its third settlement with a US state following the Department of Justice’s price-fixing investigation, agreeing to pay Georgia $3.34m in exchange for the dismissal of all claims against the company and its affiliates.
A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.